Real Estate [ 7/12 ] | Real Estate Management & Development [ 56/76 ]
NYSE | Common Stock
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.
It operates in two segments, Healthcare and Real Estate.
The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.
The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors.
In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation.
Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 13, 24 | 0.26 Increased by +282.19% | - |
| Jan 10, 24 | -0.15 Decreased by -322.40% | - |
| Oct 30, 23 | 0.05 Increased by +121.57% | - |
| Jun 13, 23 | -0.06 Increased by +78.04% | - |
| Mar 15, 23 | -0.14 Decreased by -17.00% | - |
| Dec 13, 22 | 0.07 Increased by +101.07% | - |
| Oct 31, 22 | -0.24 Increased by +65.92% | - |
| Jun 14, 22 | -0.28 Decreased by -86.67% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Apr 30, 24 | 336.00 K Increased by +373.24% | -32.35 M Decreased by -2.07 K% | Decreased by -9.63 K% Decreased by -358.80% |
| Jan 31, 24 | 68.00 K Decreased by -2.86% | 6.05 M Increased by +285.95% | Increased by +8.89 K% Increased by +291.42% |
| Oct 31, 23 | 68.00 K Decreased by -2.86% | -3.64 M Increased by +30.13% | Decreased by -5.35 K% Increased by +28.08% |
| Jul 31, 23 | 68.00 K Decreased by -1.45% | 1.22 M Increased by +126.28% | Increased by +1.79 K% Increased by +126.66% |
| Apr 30, 23 | 71.00 K Decreased by -91.89% | -1.49 M Increased by +73.14% | Decreased by -2.10 K% Decreased by -230.98% |
| Jan 31, 23 | 70.00 K Decreased by -93.69% | -3.25 M Decreased by -40.11% | Decreased by -4.65 K% Decreased by -2.12 K% |
| Oct 31, 22 | 70.00 K Decreased by -93.18% | -5.21 M Increased by +95.97% | Decreased by -7.44 K% Increased by +40.98% |
| Jul 31, 22 | 69.00 K Decreased by -92.88% | -4.64 M Increased by +62.53% | Decreased by -6.72 K% Decreased by -426.23% |